Features of hemorheology and hemostasis in inflammatory bowel disease in children, correction of changes: a literature review
Abstract
Inflammatory bowel disease (IBD) is a serious problem in pediatric gastroenterology and requires deeper and more detailed study. The pathogenesis of IBD is based on a genetic predisposition, the implementation of which occurs under the influence of aggressive environmental factors and the state of the intestinal microflora, which leads to a cascade of inflammatory reactions in the intestinal wall. However, to date, the mechanism of IBD development remains incompletely understood, and therefore conducting a literature review on the features of hemorheology and hemostasis in children with this pathology is relevant for the subsequent study of this issue in order to optimize therapy. Materials and methods of research. The search for literature sources was carried out using the library platforms: PubMed, eLIBRARY. All sources are no more than five years old. Conclusion. Based on a study of hemorheology and hemostasis in children with IBD, a positive effect of hyperbaric oxygen therapy, taking into account the individual characteristics of each patient, has been demonstrated. This leads to the development of practical recommendations aimed at increasing the effectiveness of basic therapy.
References
Fabián O., Kamaradová K. Morphology of inflammatory bowel diseases (IBD). Cesk Patol. 2022;58(1):27–37.
Kelsen J.R., Russo P., Sullivan K.E. Early-Onset Inflammatory Bowel Disease. Immunol Allergy Clin North Am. 2019;39(1):63–79. DOI: 10.1016/j.iac.2018.08.008.
Fuller M.K. Pediatric inflammatory bowel disease: special considerations. Surg Clin North Am. 2019;99(6):1177–1183. DOI: 10.1016/j.suc.2019.08.008.
Spencer E.A., Dubinsky M.C. Precision medicine in pediatric inflammatory bowel disease. Pediatr Clin North Am. 2021;68(6):1171–1190. DOI: 10.1016/j.pcl.2021.07.011.
Na S.Y., Kim Y.S. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs. Korean J Intern Med. 2022;37(5):906–919. DOI: 10.3904/kjim.2022.152.
Chatelain D., Moslemi A., Dreau A., Clement M. Les maladies inflammatoires chroniques intestinales (MICI) et tube digestif haut [Inflammatory bowel diseases and upper gastrointestinal tract]. Ann Pathol. 2023;43(3):192–201. (In French). DOI: 10.1016/j.annpat.2022.12.002.
Guan Q. A Comprehensive Review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238. DOI: 10.1155/2019/7247238.
Peric S., Todorovic Z., Zdravkovic N., Gogic A., Simovic S., Grbovic V., Maksic M., Jakovljevic S., Milovanovic O., Zdravkovic N. Treatment of ulcerative colitis: impact on platelet aggregation. Medicina (Kaunas). 2023;59(9):1615. DOI: 10.3390/medicina59091615.
Meianu C., Andrei S., Diculescu M., Longrois D., Guinot P.G., Droc G. Rotational Thromboelastometry Coagulation Parameters (ROTEM®) may be discriminative for active inflammatory bowel disease: a prospective observational study. J Gastrointestin Liver Dis. 2023;32(3):298–305. DOI: 10.15403/jgld-4810.
Melazzini F., Calabretta F., Lenti M.V., Di Sabatino A. Venous thromboembolism in chronic gastrointestinal disorders. Expert Rev Gastroenterol Hepatol. 2022;16(5):437–448. DOI: 10.1080/17474124.2022.2072295.
Szakács Z., Csiszár B., Kenyeres P., Sarlós P., Erőss B., Hussain A., Nagy Á., Kőszegi B., Veczák I., Farkas N., Bódis E., Márta K., Szentesi A., Tőkés-Füzesi M., Berki T., Vincze Á., Tóth K., Hegyi P., Bajor J. Haemorheological and haemostatic alterations in coeliac disease and inflammatory bowel disease in comparison with non-coeliac, non-IBD subjects (HERMES): a case-control study protocol. BMJ Open. 2019;9(3):e026315. DOI: 10.1136/bmjopen-2018-026315.
Iourinets J., Sawalski C., Desai P., Sutherland D., Shah P., Bruno E., Arora P., Malik M., Patel A., Akhtar T., Fareed J., Brailovsky Y., Naik A., Darki A. Prevalence and outcome of acute pulmonary embolism in hospitalized patients with a history of inflammatory bowel disease. Thromb Res. 2024;239:109035. DOI: 10.1016/j.thromres.2024.05.008.
Keller K., Sivanathan V., Schmitt V.H., Ostad M.A., Münzel T., Espinola-Klein C., Hobohm L. Incidence and impact of venous thromboembolism in hospitalized patients with Crohn’s disease. Thromb Res. 2022;219:77–85. DOI: 10.1016/j.thromres.2022.09.009.
Borjas-Howard J.F., Leeuw K., Rutgers A., Meijer K., Tichelaar VYIG. Risk of recurrent venous thromboembolism in autoimmune diseases: a systematic review of the literature. Semin Thromb Hemost. 2019;45(2):141–149. DOI: 10.1055/s-0038-1661387.
Lugonja S.I., Pantic I.L., Milovanovic T.M., Grbovic V.M., Djokovic B.M., Todorovic Ž.D., Simovic S.M., Medovic R.H., Zdravkovic N.D., Zdravkovic N.D. Atherosclerotic cardiovascular disease in inflammatory bowel disease: the role of chronic inflammation and platelet aggregation. Medicina (Kaunas). 2023;59(3):554. DOI: 1.0.3390/medicina59030554.
Petrey A.C., de la Motte CA. Hyaluronan in inflammatory bowel disease: Cross-linking inflammation and coagulation. Matrix Biol. 2019;78–79:314–323. DOI: 10.1016/j.matbio.2018.03.011.
Hu W., Li P., Zeng N., Tan S. Exploring the hub mechanisms of ischemic stroke based on protein-protein interaction networks related to ischemic stroke and inflammatory bowel disease. Sci Rep. 2023;13(1):1741. DOI: 10.1038/s41598-023-27459-w.
Wu H., Xu M. [Platelet activation in inflammatory bowel disease]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019;44(8):931–934. (In Chinese). DOI: 10.11817/j.issn.1672-7347.2019.180192.
Niu Y., Li A., Xu W., Zhang R., Mei R., Zhang L., Zhou F., Pan Q., Yan Y. Platelet activation stimulates macrophages to enhance ulcerative colitis through PF4/CXCR3 signaling. Int J Mol Med. 2025;55(5):78. DOI: 10.3892/ijmm.2025.5519.
Anka Idrissi D., Senhaji N., Aouiss A., Khalki L., Tijani Y., Zaid N., Marhoume F.Z., Naya A., Oudghiri M., Kabine M., Zaid Y. IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn’s disease and new therapeutic targets. Arch Pharm Res. 2021;44(1):117–132. DOI: 10.1007/s12272-020-01296-1.
Detrez I., Thomas D., Van Steen K., Ballet V., Peeters M., Hoylaerts M.F., Van Assche G., Vermeire S., Ferrante M., Gils A. Successful infliximab treatment is associated with reversal of clotting abnormalities in inflammatory bowel disease patients. J Clin Gastroenterol. 2020;54(9): 819–825. DOI: 10.1097/MCG.0000000000001290.
Sano Y., Tomiyama T., Yagi N., Ito Y., Honzawa Y., Tahara T., Ikeura T., Fukui T., Shimoda S., Naganuma M. Platelet activation through CD62P and the formation of platelet-monocyte complexes are associated with the exacerbation of mucosal inflammation in patients with ulcerative colitis. Sci Rep. 2024;14(1):28055. DOI: 10.1038/s41598-024-78462-8.
Boccatonda A., Balletta M., Vicari S., Hoxha A., Simioni P., Campello E. The journey through the pathogenesis and treatment of venous thromboembolism in inflammatory bowel diseases: a narrative review. Semin Thromb Hemost. 2023;49(7):744–755. DOI: 10.1055/s-0042-1758869.
Lagrange J., Lacolley P., Wahl D., Peyrin-Biroulet L., Regnault V. Shedding light on hemostasis in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(6):1088–1097.e6. DOI: 10.1016/j.cgh.2019.12.043.
Lagrange J., Ahmed M.U., Arnone D., Lacolley P., Regnault V., Peyrin-Biroulet L., Denis C.V. Implications of von Willebrand factor in inflammatory bowel diseases: beyond bleeding and thrombosis. Inflamm Bowel Dis. 2024;30(12):2500–2508. DOI: 10.1093/ibd/izae142.
Leibovitzh H., Lee S.H., Xue M., Raygoza Garay J.A., Hernandez-Rocha C., Madsen K.L., Meddings J.B., Guttman D.S., Espin-Garcia O., Smith M.I., Goethel A., Griffiths A.M., Moayyedi P., Steinhart A.H., Panaccione R., Huynh H.Q., Jacobson K., Aumais G., Mack D.R., Abreu M.T., Bernstein C.N., Marshall J.K., Turner D., Xu W. CCC GEM Project Research Consortium; Turpin W., Croitoru K. Altered gut microbiome composition and function are associated with gut barrier dysfunction in healthy relatives of patients with Crohn’s disease. Gastroenterology. 2022;163(5): 1364–1376.e10. DOI: 10.1053/j.gastro.2022.07.004.
Dull K., Fazekas F., Törőcsik D. Factor XIII-A in diseases: role beyond blood coagulation. Int J Mol Sci. 2021;22(3):1459. DOI: 10.3390/ijms22031459.
Ollech J.E., Waizbard A., Lubetsky A., Kopylov U., Goren I., Dotan I., Yanai H. Venous thromboembolism among patients with inflammatory bowel diseases is not related to increased thrombophilia: a case-control study. J Clin Gastroenterol. 2022;56(3):e222–e226. DOI: 10.1097/MCG.0000000000001578.
Schellenberg C., Lagrange J., Ahmed M.U., Arnone D., Campoli P., Louis H., Touly N., Caron B., Plénat F., Perrin J., Lenting P.J., Regnault V., Lacolley P., Denis C.V., Peyrin-Biroulet L. The role of platelets and von Willebrand factor in the procoagulant phenotype of inflammatory bowel disease. J Crohns Colitis. 2024;18(5): 751–761. DOI: 10.1093/ecco-jcc/jjad198.
Klavina P.A., Leon G., Curtis A.M., Preston RJS. Dysregulated haemostasis in thrombo-inflammatory disease. Clin Sci (Lond). 2022;136(24):1809–1829. DOI: 10.1042/CS20220208.
Leppkes M., Lindemann A., Gößwein S., Paulus S., Roth D., Hartung A., Liebing E., Zundler S., Gonzalez-Acera M., Patankar J.V., Mascia F., Scheibe K., Hoffmann M., Uderhardt S., Schauer C., Foersch S., Neufert C., Vieth M., Schett G., Atreya R., Kühl A.A., Bleich A., Becker C., Herrmann M., Neurath M.F. Neutrophils prevent rectal bleeding in ulcerative colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis. Gut. 2022;71(12):2414–2429. DOI: 10.1136/gutjnl-2021-324725.
Leon G., Klavina P.A., Rehill A.M., Cooper SEJ., Dominik A., Basavarajappa S.C., O’Donnell J.S., Hussey S., Walsh P.T., Preston RJS. Tissue factor-dependent colitogenic CD4+ T cell thrombogenicity is regulated by activated protein C signalling. Nat Commun. 2025;16(1):1677. DOI: 10.1038/s41467-025-57001-7.
Lagrange J., Lacolley P., Wahl D., Peyrin-Biroulet L., Regnault V. Shedding light on hemostasis in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2021;19(6):1088–1097.e6. DOI: 10.1016/j.cgh.2019.12.043.
Liu P., Li Y., Wang R., Ren F., Wang X. Oxidative stress and antioxidant nanotherapeutic approaches for inflammatory bowel disease. Biomedicines. 2021;10(1):85. DOI: 10.3390/biomedicines10010085.
Alenazi N., Alsaeed H., Alsulami A., Alanzi T. A review of hyperbaric oxygen therapy for inflammatory bowel disease. Int J Gen Med. 2021;14:7099–7105. DOI: 10.2147/IJGM.S336678.
